Advertisement
Advertisement
U.S. Markets open in 1 hr 28 mins
Advertisement
Advertisement
Advertisement
Advertisement

Xencor, Inc. (XNCR)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
32.92+1.22 (+3.85%)
At close: 04:00PM EST
32.92 0.00 (0.00%)
After hours: 05:00PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close31.70
Open32.43
Bid32.27 x 800
Ask33.52 x 800
Day's Range31.93 - 33.03
52 Week Range19.35 - 35.92
Volume484,130
Avg. Volume343,658
Market Cap1.925B
Beta (5Y Monthly)0.60
PE Ratio (TTM)N/A
EPS (TTM)-1.21
Earnings DateFeb 21, 2023 - Feb 27, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est48.25
  • Motley Fool

    Why Shares of Zencor Rose This Week

    Shares of Xencor (NASDAQ: XNCR) rose 12.6% this week as of Thursday afternoon, according to data provided by S&P Global Market Intelligence. The stock closed at $28.83 on Friday and then rose as high as $33.06 on Thursday. Xencor stock was up as high as 14.7% for the week before falling a bit later in the day Thursday.

  • Business Wire

    Xencor Highlights 2023 Corporate Priorities and Provides Portfolio Updates

    MONROVIA, Calif., January 09, 2023--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced 2023 corporate priorities and provided multiple clinical development updates.

  • PR Newswire

    Caris Life Sciences and Xencor Expand Target Discovery Collaboration for Novel XmAb® Antibody Drug Candidates

    Caris Life Sciences®(Caris), the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare, and Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced an expansion of their collaboration to research, develop and commercialize novel XmAb® bispecific and multi-specific antibodies directed agai

Advertisement
Advertisement